J&J Outlines Novel Cancer Strategy During Business Update
This article was originally published in The Pink Sheet Daily
Executive Summary
Newly approved Zytiga, for prostate cancer, loses U.S. exclusivity in 2016, but J&J looks to ex-U.S. approvals for market protection.
You may also be interested in...
Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal
Given the early-stage nature of the collaboration, Aveo will receive $15 million upfront for preclinical antibodies targeting the RON receptor.
Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal
Given the early-stage nature of the collaboration, Aveo will receive $15 million upfront for preclinical antibodies targeting the RON receptor.
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.